Our chief scientific officer and co-founder Noah Davidsohn will be presenting at the American Society of Gene & Cell Therapy 2024 meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually. 🧬🧬
“We’re excited to share data at ASGCT 2024 on our RJB-0402 gene therapy which targets key disease-mediating pathways in arrhythmogenic cardiomyopathy (ACM),” said Noah Davidsohn, PhD., Chief Scientific Officer at Rejuvenate Bio. “ACM is an inherited disease caused by mutations in one of several genes encoding desmosomal proteins, and there is an urgent need for better treatment options. If our approach proves effective to treat ACM, it would have a dramatic impact on the profound burden this disease has on patients and their families.”
Title: AAV FGF21 Gene Therapy as a Variant Agnostic Treatment for Arrhythmogenic Cardiomyopathy
Session Type: In-Person Oral Presentation
Session Title: Next Generation Gene & Cell Therapies for Heart, Lung, and Kidney Diseases
Abstract Number: 79
Location: Room 314-317
Session Date/Time: Wednesday May 8, 2024 1:30 PM - 3:15 PM
Read the full release:
👇👇
https://lnkd.in/e9Qhtvws